▲ +56.99% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $36.25, with a high forecast of $53.00 and a low forecast of $27.00. The average price target represents a 56.99% upside from the last price of $23.09.
The current consensus among 7 investment analysts is to buy stock in Protagonist Therapeutics. This Buy consensus rating has held steady for over two years.
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.